Thermo Fisher Scientific provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics worldwide. The company was founded in 1956 and is based in Waltham, Massachusetts.
TMO Price Forecast Based on DCF Valuation
DCF Fair Value Target:
We started the process of determining a valid price forecast for Thermo Fisher Scientific Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Thermo Fisher Scientific Inc ranked in the 35th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. As for the metrics that stood out in our discounted cash flow analysis of Thermo Fisher Scientific Inc, consider:
The company's debt burden, as measured by earnings divided by interest payments, is 5.96; that's higher than 57.66% of US stocks in the Healthcare sector that have positive free cash flow.
91% of the company's capital comes from equity, which is greater than 74.38% of stocks in our cash flow based forecasting set.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as TMO, try RGEN, A, IART, MD, and BIO.
Drugs of abuse testing are an advanced technique for detecting an illegal or prescribed substance in the sample such as hair, blood, urine, saliva, or sweat. This process includes the screening test followed by the identification of drugs present in
According to the new market research report "UV/Visible Spectroscopy Market by Instrument Type (Single-Beam, Dual-Beam), Application (Academic Application, Industrial Application), End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes) - Global Forecast to 2025", published by MarketsandMarkets™, the market
Thermo Fisher Scientific Inc. has inked a definitive agreement to acquire Mesa Biotech Inc., a privately held molecular diagnostics company with a point-of-care (POC) platform, for approximately $450 million in cash. The scientific instruments and testing giant said it will pay an additional $100 million in cash upon the completion of certain milestones. The planned acquisition will expand Thermo Fisher’s franchise of diagnostic test options with a novel platform that enables nucleic acid polymerase chain reaction (PCR) testing at the point of care.
Diagnostic Tests market report provides historical data along with future forecast and detailed analysis for the market on a global and regional level. This analysis gives an examination of various segments that are relied upon to witness the quickest development
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced it has entered into a definitive agreement to acquire Mesa Biotech, Inc., a privately held molecular diagnostic company, for approximately $450 million in cash. Under the terms of the agreement, Thermo Fisher will pay up to an additional $100 million in cash upon the completion of certain milestones following the close of the transaction.